Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alsu G. Zalevskaya"'
Autor:
Nataliya S. Novoselova, Anna A. Mosikian, Olga Y. Martyanova, Evgenya M. Patrakeeva, Alsu G. Zalevskaya
Publikováno v:
Сахарный диабет, Vol 21, Iss 6, Pp 472-479 (2018)
Background: Only a little percent of chronically ill patients was found to follow physicians’ prescriptions. One of the reasons for this issue is misunderstanding of recommendations due to inappropriate interpretation of medical terms, contained in
Externí odkaz:
https://doaj.org/article/e2b806c8604a4e359177949b3b2458fe
Autor:
Klemen Dovc, Gül Yeşiltepe Mutlu, Yury I. Philippov, Dmitry N. Laptev, Evgenia M. Patrakeeva, Lubov O. Chernilova, Alsu G. Zalevskaya, Marina V. Shestakova, Tadej Battelino
Publikováno v:
Сахарный диабет, Vol 21, Iss 3, Pp 206-216 (2018)
BACKGRAUND: A closed-loop glucose control system or ‘artificial pancreas’ consists of three components – a Continuous Glucose Monitor (CGM), infusion pumps to deliver hormone(s) and a sophisticated dosing algorithm to control hormone delivery.
Externí odkaz:
https://doaj.org/article/bb3b843fbf3f4df295dbcc4833fa4fb2
Autor:
S. R. Aravind, Kiran P. Singh, Liliia Mogylnytska, Alsu G. Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee
Publikováno v:
Diabetes Therapy. 13:1299-1310
We compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (70% intermediate SAR341402 protamine and 30% rapid SAR341402 solution) (SARThis phase 3, randomized, open-label, multinational, 26-week tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0caa3cbb19b79639d8e3fe739120f26b
https://doi.org/10.1007/s13300-022-01279-z
https://doi.org/10.1007/s13300-022-01279-z
Autor:
S. R. Aravind, Kiran P. Singh, Grace Aquitania, Liliia Mogylnytska, Alsu G. Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee
Publikováno v:
Diabetes therapy : research, treatment and education of diabetes and related disorders. 13(5)
This study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARThis 26-week, open-label, phase 3 trial enrolled 402 people with T1D (n = 105) or T2D (n = 297) previously treated with premix in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bebbeff4fe4b05ba639824f46cddc001
https://pubmed.ncbi.nlm.nih.gov/35420397
https://pubmed.ncbi.nlm.nih.gov/35420397